This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic

Arch Dermatol. 2000;136:410-411.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

TOXIC EPIDERMAL necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are perhaps the most dramatic and severe adverse cutaneous reactions to drugs.¹ Both of these related mucocutaneous disorders have associated high rates of morbidity and mortality.² In this issue of the ARCHIVES, the group from Hôpital Henri Mondor in Créteil, France, presents the results of a retrospective study of the effect of the early withdrawal of causative drugs on the survival of patients with TEN and SJS.³ Because of the seriousness of these conditions and the lack of definitively effective treatment, there is a large body of literature advocating a variety of treatments, some of which are clearly beneficial, some of which are more likely to be harmful than helpful, and some of which are of great interest but still of unproven benefit.

The article by Garcia-Doval et al³ provides a straightforward message. If there is a strong suspicion that a patient . . . [Full Text of this Article]

RELATED ARTICLE

Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: Does Early Withdrawal of Causative Drugs Decrease the Risk of Death?
Ignacio Garcia-Doval, Laurence LeCleach, Hélène Bocquet, Xose-Luis Otero, and Jean-Claude Roujeau
Arch Dermatol. 2000;136(3):323-327.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reducing Medication Errors and Increasing Patient Safety: Case Studies in Clinical Pharmacology
Benjamin
J Clin Pharmacol 2003;43:768-783.
ABSTRACT | FULL TEXT  

Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression
Bachot et al.
Arch Dermatol 2003;139:33-36.
ABSTRACT | FULL TEXT  

Recurrent Erythema Multiforme/Stevens-Johnson Syndrome: Response to Mycophenolate Mofetil
Davis et al.
Arch Dermatol 2002;138:1547-1550.
FULL TEXT